Preparation and characterization of solid dispersions of Carvedilol with PVP K30

Research in Pharmaceutical Sciences

Volumn 5, Issue 1, 2010, Pages 45-52

  Sharma, A ^a   Jain, C P ^b  

^a Bhupal Noble s University   (India)

^b M L SUKHADIA UNIVERSITY   (India)

Author keywords

Carvedilol; Dissolution rate; PVP K30; Solid dispersions; Solubility

Indexed keywords

CARVEDILOL; POVIDONE; POVIDONE K30; SOLVENT; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG BIOAVAILABILITY; DRUG PURITY; DRUG SOLUBILITY; DRUG STORAGE; EVAPORATION; THERMOGRAPHY; X RAY DIFFRACTION;

EID: 78650667627     PISSN: 17355362     EISSN: 17359414     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Ruffolo RR, Boyle DA, Brooks DP, Feuerstein GZ, Venuti RP, Lukas MA, et al. Carvedilol: a novel cardiovascular drag with multiple actions. Cardiovasc Drug Rev. 1992;10:127-157.
2. Tanwar YS, Chauhan CS, Sharma A. Development and evaluation of Carvedilol transdermal patches. Acta Pharm. 2007;57:151-159.
3. Dunn CJ, Lea AP, Wagstaff AJ. Carvedilol: a reappraisal of its pharmacological β -blockers in left ventricular dysfunction and heart failure. Drags. 1997;54:161-169.
4. Loftsson T, Vogensen SB, Desbos C, Jansook P. Carvedilol: solubilization and cyclodextrin complexation: a technical note, AAPS Pharm Sci Tech. 2008;9:425-430.
5. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M., Lennernas H, Hussain AS, et al. Molecular properties of WHO essential drags and provisional biopharmaceutical classification. Mol Pharm. 2004;1:85-96.
6. Ruffolo RRJr, Feuerstein GZ. Carvedilol: a novel multiple action antihypertensive drag that provides major organ protection. Cardiovasc Drags Ther. 1997;11:247-256.
7. Thummel KE, Shen DD. Goodman and Gilman's The Pharmacological Basis of Therapeutics, loth ed. New York: McGraw-Hill companies; 2001. p. 1936.
8. Wei L, Sun P, Nie S, Pan W. Preparation and evaluation of SEDDS and SMEDDS containing Carvedilol. Drag Dev Ind Pharm. 2005;31:785-794.
9. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci. 1971;60:1281-1302.
10. Ford JL. The current status of solid dispersions. Pharm Acta HeIv. 1986;61:69-88.
11. Shah J, Vasanti S, Anroop B, Vyas H. Enhancement of dissolution rate of valdecoxib by solid dispersions technique with PVP K 30 & PEG 4000: preparation and in vitro evaluation. J Incl Phenom Macrocycl Chem. 2009;63:69-75.
12. Gupta P, Kakumanu VK, Bansal AK. Stability and solubility of celecoxib-PVP amorphous dispersions: a molecular perspective. Pharm Res. 2004;21:1762-1769.
13. Chanda R, Kapoor VK, Kumar A. Analytical techniques used to characterize drug-polyvinylpyrrolidone systems in solid and liquid states- An overview. J Scient Ind Res. 2006;65:459-469.
14. Chen S, Zhu J, Ma F, Fang Q, Li Y. Preparation and characterization of solid dispersions of dipyridamole with a carrier copolyvidonum Plasdone®Drag Dev Ind Pharm. 2007;33:888-899.
15. Higuchi T, Connors KA. Phase-solubility techniques. Adv Anal Chem. Instr. 1965;4:117-212.
16. Thierry VH, Geraldine P, Sandrine HH, Brigitte E, Luc D. Determination of the free/included piroxicam ratio in cyclodextrin complexes: comparison between UV spectrophotometry and differential scanning calorimetry. Eur J Pharm Sci. 2002;15:347-353.
17. The United States Pharmacopoeia, 24th rev, and The National Formulary, 19th ed. Vol 2. Rockville, MD: USP Convention; 2000.
18. Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol. 1975;27:48-49.
19. Pokharkar V, Khanna A, Venkatpurwar V, Dhar S, Mandpe L. Ternary complexation of Carvedilol, β-cyclodextrin and citric acid for mouth-dissolving tablet formulation. Acta Pharm. 2009;59:121-132.
20. Sammour OA, Hammad MA, Megrab NA, Zidan AS. Formulation and optimization of mouth dissolve tablets containing rofecoxib solid dispersions. AAPS Pharm Sci Tech. 2006;7:E1-E9.
21. Thybo P, Kristensen J, Hovgaard L. Characterization and physical stability of tolfenamic acid-PVP K30 solid dispersions. Pharm Dev Technol. 2007;12:43-53.
22. Bettinetti GP, Mura P. Dissolution properties of naproxen in combinations with polyvinylpyrrolidone. Drag Dev Ind Pharm. 1994;20:1353-1366.
23. Abdul-Fattah AM, Bhargava HN. Preparation and in vitro evaluation of solid dispersions of halofantrine. Int J Pharm. 2002;235:17-33.